ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in derivatives that have similar daily performance characteristics as the inverse of the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund.
Basic Details
Issuer ProShares
Fund NameProShares Ultra Nasdaq Biotechnology
Tax ClassificationRegulated Investment Company
SymbolNASDAQ:BIB
Inception Date4/6/2010
Fund ManagerMichael Neches, Tarak Dave
Phone+1-240-4976400
Fund Focus
Asset ClassEquity
BenchmarkNasdaq Biotech Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America
Fund Statistics
Assets Under Management$193.76 million
Average Daily Volume$162,193.00
Discount/Premium-0.09%
ETF Expenses
Management Fee0.75%
Other Expenses0.29%
Total Expenses1.04%
Fee Waiver-0.09%
Net Expenses0.95%
Administrator, Advisor and Custodian
AdministratorJ.P. Morgan Investor Services Co.
AdvisorProShare Advisors LLC
CustodianJPMorgan Chase Bank, N.A.
DistributorSEI Investments Distribution Co.
Transfer AgentJPMorgan Chase Bank, N.A.
Trustee
Lead Market MakerVirtu Financial
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Frequently Asked Questions
What is ProShares Ultra Nasdaq Biotechnology's stock symbol?
ProShares Ultra Nasdaq Biotechnology trades on the NASDAQ under the ticker symbol "BIB."
Has ProShares Ultra Nasdaq Biotechnology been receiving favorable news coverage?
Press coverage about BIB stock has trended extremely positive on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. ProShares Ultra Nasdaq Biotechnology earned a media sentiment score of 5.0 on InfoTrie's scale. They also assigned news coverage about the exchange traded fund a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for ProShares Ultra Nasdaq Biotechnology.
What other stocks do shareholders of ProShares Ultra Nasdaq Biotechnology own?
Who are ProShares Ultra Nasdaq Biotechnology's major shareholders?
ProShares Ultra Nasdaq Biotechnology's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Tower Research Capital LLC TRC (0.76%), SkyOak Wealt LLC (0.41%), Capital Investment Advisors LLC (0.33%), Toth Financial Advisory Corp (0.25%), Koshinski Asset Management Inc. (0.19%) and Capital Analysts LLC (0.05%).
Which major investors are selling ProShares Ultra Nasdaq Biotechnology stock?
BIB stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG and Capital Analysts LLC.
Which major investors are buying ProShares Ultra Nasdaq Biotechnology stock?
BIB stock was bought by a variety of institutional investors in the last quarter, including Tower Research Capital LLC TRC, SkyOak Wealt LLC, Koshinski Asset Management Inc., Boston Private Wealth LLC, Pacitti Group Inc., Toth Financial Advisory Corp, Ladenburg Thalmann Financial Services Inc. and US Bancorp DE.
How do I buy shares of ProShares Ultra Nasdaq Biotechnology?
Shares of BIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ProShares Ultra Nasdaq Biotechnology's stock price today?
One share of BIB stock can currently be purchased for approximately $64.34.
How big of a company is ProShares Ultra Nasdaq Biotechnology?
What is ProShares Ultra Nasdaq Biotechnology's official website?
How can I contact ProShares Ultra Nasdaq Biotechnology?
ProShares Ultra Nasdaq Biotechnology's mailing address is SUITE 1000, 7501 WISCONSIN AVENUE, BETHESDA, MD 20814, United States. The exchange traded fund can be reached via phone at +1-240-4976400.
MarketBeat Community Rating for ProShares Ultra Nasdaq Biotechnology (NASDAQ BIB)
MarketBeat's community ratings are surveys of what our community members think about ProShares Ultra Nasdaq Biotechnology and other stocks. Vote "Outperform" if you believe BIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
